Answers are grounded in this paper and cite their sources.
Radiotherapy for triple-negative breast cancer (TNBC) is often limited by intrinsic tumor radioresistance. The clinically approved radiosensitizer sodium glycididazole (CMNa) is restricted by its hypoxia-dependent activity and lack of tumor targeting. Integrin-targeted gold nanoclusters have been extensively investigated as radiosensitizers, yet direct head-to-head comparisons with CMNa are lacking. We synthesized RGDfC-gold nanoclusters (RGDfC-AuNCs) via one-step biomineralization and compared them with CMNa in 4T1 murine TNBC cells and tumor-bearing mice. The nanoclusters showed ultrasmall size, good stability, and exhibited enhanced cellular uptake relative to non-targeted controls. In vitro, radiosensitization performance was assessed by CCK‑8 assays under normoxic and CoCl 2 ‑mimicked pseudo‑hypoxic conditions. Under equal-total-mass dosing conditions, RGDfC-AuNCs showed superior radiosensitizing trends relative to CMNa across the range of radiation doses tested (2–8 Gy) in both oxygen environments. In 4T1 tumor-bearing mice, RGDfC-AuNCs plus radiotherapy achieved superior tumor growth inhibition (68.29% vs. 50.61%) and a markedly higher sensitization enhancement ratio (2.01 vs. 1.47) compared with CMNa plus radiotherapy, and tumor sections displayed elevated γ-H2AX foci, suggesting enhanced DNA damage. Neither agent induced obvious acute systemic toxicity in hematological, biochemical and histopathological examinations. Collectively, these head‑to‑head observations illustrate the favorable radiosensitization profile of RGDfC‑AuNCs relative to the clinical agent CMNa under the tested conditions, providing a reference for nanocluster-based TNBC radiosensitization.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: